VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q37383824 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000249.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q37383824‏
024 ‎‡a 0000-0003-3505-1310‏ ‎‡2 orcid‏
024 ‎‡a 49461682500‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q37383824‏
100 0 ‎‡a Sandra Ribeiro‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Sandra Ribeiro‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Sandra Ribeiro‏ ‎‡c investigadora‏ ‎‡9 ast‏
400 0 ‎‡a Sandra Ribeiro‏ ‎‡c ricercatrice‏ ‎‡9 it‏
400 0 ‎‡a Sandra Ribeiro‏ ‎‡c investigadora‏ ‎‡9 es‏
670 ‎‡a Author's Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis‏
670 ‎‡a Author's Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.‏
670 ‎‡a Author's Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses.‏
670 ‎‡a Author's Comparison of Bio-Plex measurements with standard techniques‏
670 ‎‡a Author's Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat.‏
670 ‎‡a Author's Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia‏
670 ‎‡a Author's Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model‏
670 ‎‡a Author's Iron therapy in chronic kidney disease: Recent changes, benefits and risks‏
670 ‎‡a Author's Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses‏
670 ‎‡a Author's Main Determinants of PON1 Activity in Hemodialysis Patients‏
670 ‎‡a Author's Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients‏
670 ‎‡a Author's Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.‏
670 ‎‡a Author's Oxidized low-density lipoprotein and lipoprotein‏
670 ‎‡a Author's Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.‏
670 ‎‡a Author's Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia‏
670 ‎‡a Author's Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.‏
670 ‎‡a Author's Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat.‏
670 ‎‡a Author's Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose‏
670 ‎‡a Author's Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia‏
670 ‎‡a Author's rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits‏
670 ‎‡a Author's Risk factors for mortality in hemodialysis patients: two-year follow-up study.‏
670 ‎‡a Author's Vascular access versus the effect of statins on inflammation and fibrinolysis in renal dialysis patients‏
909 ‎‡a (scopus) 49461682500‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000335051310‏ ‎‡9 1‏
919 ‎‡a resistancetorecombinanthumanerythropoietintherapyinaratmodelofchronickidneydiseaseassociatedanemia‏ ‎‡A Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia‏ ‎‡9 1‏
919 ‎‡a irontherapyinchronickidneydiseaserecentchangesbenefitsandrisks‏ ‎‡A Iron therapy in chronic kidney disease: Recent changes, benefits and risks‏ ‎‡9 1‏
919 ‎‡a majordeterminantsofbmp2serumlevelsinhemodialysispatients‏ ‎‡A Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients‏ ‎‡9 1‏
919 ‎‡a maindeterminantsofpon1activityinhemodialysispatients‏ ‎‡A Main Determinants of PON1 Activity in Hemodialysis Patients‏ ‎‡9 1‏
919 ‎‡a renalriskbenefitdeterminantsofrecombinanthumanerythropoietintherapyintheremnantkidneyratmodelhypertensionanaemiainflammationanddrugdose‏ ‎‡A Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose‏ ‎‡9 1‏
919 ‎‡a recombinanthumanerythropoietininducederythropoiesisregulateshepcidinexpressionoverironstatusintherat‏ ‎‡A Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat.‏ ‎‡9 1‏
919 ‎‡a circulatingcellfreednalevelsinhemodialysispatientsanditsassociationwithinflammationironmetabolismandrhepodoses‏ ‎‡A Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses.‏ ‎‡9 1‏
919 ‎‡a bodymassindexandresistancetorecombinanthumanerythropoietintherapyinmaintenancehemodialysispatients‏ ‎‡A Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.‏ ‎‡9 1‏
919 ‎‡a adiponectinisanindependentpredictoroftissueplasminogenactivatorlevelsinpatientsunderhaemodialysis‏ ‎‡A Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis‏ ‎‡9 1‏
919 ‎‡a ironhepcidindysmetabolismanemiaandrenalhypoxiainflammationandfibrosisintheremnantkidneyratmodel‏ ‎‡A Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model‏ ‎‡9 1‏
919 ‎‡a ironasthekeymodulatorofhepcidinexpressioninerythroidantibodymediatedhypoplasia‏ ‎‡A Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia‏ ‎‡9 1‏
919 ‎‡a comparisonofbioplexmeasurementswithstandardtechniques‏ ‎‡A Comparison of Bio-Plex measurements with standard techniques‏ ‎‡9 1‏
919 ‎‡a impairedrenalendothelialnitricoxidesynthaseandreticulocyteproductionasmodulatorsofhypertensioninducedbyrhuepointherat‏ ‎‡A Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat.‏ ‎‡9 1‏
919 ‎‡a markersofincreasedcardiovascularriskinpostmenopausalwomenfocusonoxidizedldlandhdlsubpopulations‏ ‎‡A Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.‏ ‎‡9 1‏
919 ‎‡a oxidizedlowdensitylipoproteinandlipoprotein‏ ‎‡A Oxidized low-density lipoprotein and lipoprotein‏ ‎‡9 1‏
919 ‎‡a oxidizedlowdensitylipoproteinandlipoproteinalevelsinchronickidneydiseasepatientsunderhemodialysisinfluenceofadiponectinandofapolymorphismintheapolipoproteinagene‏ ‎‡A Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.‏ ‎‡9 1‏
919 ‎‡a liverironisamajorregulatorofhepcidingeneexpressionviabmpsmadpathwayinaratmodelofchronicrenalfailureundertreatmentwithhighrhuepodoses‏ ‎‡A Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses‏ ‎‡9 1‏
919 ‎‡a pathologicalandmolecularmechanismsunderlyingresistancetorecombinanthumanerythropoietintherapyintheremnantkidneyratmodelofchronickidneydiseaseassociatedanemia‏ ‎‡A Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia‏ ‎‡9 1‏
919 ‎‡a potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis‏ ‎‡A Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.‏ ‎‡9 1‏
919 ‎‡a riskfactorsformortalityinhemodialysispatients2yearfollowupstudy‏ ‎‡A Risk factors for mortality in hemodialysis patients: two-year follow-up study.‏ ‎‡9 1‏
919 ‎‡a vascularaccessversustheeffectofstatinsoninflammationandfibrinolysisinrenaldialysispatients‏ ‎‡A Vascular access versus the effect of statins on inflammation and fibrinolysis in renal dialysis patients‏ ‎‡9 1‏
919 ‎‡a rhepoforthetreatmentoferythropoietinresistantanemiainhemodialysispatientsrisksandbenefits‏ ‎‡A rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 BLBNB|000441527‏
996 ‎‡2 PTBNP|1494762‏
996 ‎‡2 PTBNP|1000384‏
996 ‎‡2 SUDOC|223711616‏
996 ‎‡2 LC|no2005007758‏
996 ‎‡2 PTBNP|1291770‏
996 ‎‡2 PTBNP|1874176‏
996 ‎‡2 ISNI|0000000070004403‏
996 ‎‡2 PTBNP|171618‏
996 ‎‡2 BNC|981060937674006706‏
996 ‎‡2 PTBNP|1727112‏
996 ‎‡2 RERO|A027455846‏
996 ‎‡2 PTBNP|224197‏
996 ‎‡2 LC|nr2006009372‏
996 ‎‡2 PTBNP|1206627‏
996 ‎‡2 LC|n 2023255099‏
996 ‎‡2 ISNI|0000000428300734‏
996 ‎‡2 SUDOC|254979416‏
996 ‎‡2 PTBNP|1586158‏
996 ‎‡2 ISNI|0000000067977685‏
996 ‎‡2 DNB|1197003401‏
996 ‎‡2 PTBNP|1672213‏
996 ‎‡2 PTBNP|1737483‏
996 ‎‡2 DNB|1244411418‏
996 ‎‡2 LC|n 2020064249‏
996 ‎‡2 BLBNB|001415383‏
996 ‎‡2 BLBNB|000332040‏
996 ‎‡2 DBC|87097968865166‏
996 ‎‡2 PTBNP|1224045‏
996 ‎‡2 PTBNP|80436‏
996 ‎‡2 J9U|987012501118005171‏
996 ‎‡2 BLBNB|000473513‏
996 ‎‡2 ISNI|0000000068924219‏
996 ‎‡2 ISNI|0000000069485019‏
996 ‎‡2 ISNI|0000000046137644‏
996 ‎‡2 SUDOC|277572398‏
996 ‎‡2 ISNI|0000000428298857‏
996 ‎‡2 PLWABN|9810587820605606‏
996 ‎‡2 BLBNB|001455590‏
996 ‎‡2 PTBNP|1203102‏
996 ‎‡2 ISNI|0000000068114101‏
996 ‎‡2 LC|no 99068433‏
996 ‎‡2 LC|n 2021250032‏
996 ‎‡2 LC|no2019003036‏
996 ‎‡2 PTBNP|1892077‏
996 ‎‡2 PTBNP|1459895‏
996 ‎‡2 PTBNP|1833744‏
996 ‎‡2 SUDOC|241684080‏
996 ‎‡2 BLBNB|000546647‏
996 ‎‡2 ISNI|0000000070099502‏
996 ‎‡2 PTBNP|35469‏
996 ‎‡2 SUDOC|237853396‏
996 ‎‡2 PTBNP|1502481‏
996 ‎‡2 PTBNP|1682077‏
996 ‎‡2 BLBNB|000499060‏
996 ‎‡2 BLBNB|000374465‏
996 ‎‡2 ISNI|0000000052432420‏
996 ‎‡2 BLBNB|000378484‏
996 ‎‡2 LC|no2023134533‏
996 ‎‡2 BIBSYS|1038023‏
996 ‎‡2 PTBNP|1745620‏
996 ‎‡2 BLBNB|001462255‏
996 ‎‡2 ISNI|0000000044529652‏
996 ‎‡2 SUDOC|137382162‏
996 ‎‡2 PTBNP|1188484‏
996 ‎‡2 ISNI|0000000507280620‏
996 ‎‡2 PTBNP|1409329‏
996 ‎‡2 PTBNP|958633‏
996 ‎‡2 LC|no2003096093‏
996 ‎‡2 PTBNP|1790094‏
996 ‎‡2 ISNI|0000000070293428‏
996 ‎‡2 PTBNP|1057404‏
996 ‎‡2 LC|no2024112940‏
996 ‎‡2 BLBNB|000261092‏
996 ‎‡2 DNB|130460591‏
996 ‎‡2 PTBNP|1593748‏
996 ‎‡2 PTBNP|228555‏
996 ‎‡2 SUDOC|195192958‏
996 ‎‡2 ISNI|0000000044164243‏
996 ‎‡2 ISNI|0000000078089456‏
996 ‎‡2 PTBNP|1574442‏
996 ‎‡2 BLBNB|001523574‏
996 ‎‡2 PTBNP|1853926‏
996 ‎‡2 BLBNB|001581187‏
996 ‎‡2 PTBNP|1665892‏
996 ‎‡2 PTBNP|1863868‏
996 ‎‡2 ISNI|0000000070525284‏
996 ‎‡2 ISNI|0000000068208693‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏